Celgene is a biopharmaceutical company focused on cancer and inflammatory diseases. It has commercial-stage products and a significant research pipeline. It has a market cap of $101.8 billion, a price to earnings ratio of 49.29. Guest Lungile Malinga from Effectus Capital and resident expert Paul Theron from Vestact decide whether is Celgene hot or not